ES2168383T3 - Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor. - Google Patents

Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.

Info

Publication number
ES2168383T3
ES2168383T3 ES95932217T ES95932217T ES2168383T3 ES 2168383 T3 ES2168383 T3 ES 2168383T3 ES 95932217 T ES95932217 T ES 95932217T ES 95932217 T ES95932217 T ES 95932217T ES 2168383 T3 ES2168383 T3 ES 2168383T3
Authority
ES
Spain
Prior art keywords
group
substituted
carboxyl
mono
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932217T
Other languages
English (en)
Inventor
Jun-Ichi Shishikura
Hiroshi Inami
Shuichi Sakamoto
Shin-Ichi Tsukamoto
Masao Sasamata
Masamichi Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2168383T3 publication Critical patent/ES2168383T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION DESCRIBE UN DERIVADO 1,2,3,4-QUINOXALINADIONA, REPRESENTADO POR LA FORMULA SIGUIENTE (I), O UNA SAL DEL MISMO, ASI COMO UN RECEPTOR DE GLICINA TIPO NMDA Y/O UN ANTAGONISTA DEL RECEPTOR AMPA, O UN INHIBIDOR DE LA NEUROTOXICIDAD DEL ACIDO CAINICO, QUE CONTIENE DICHO DERIVADO O SU SAL. ADEMAS, SE PRESENTA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO Y UN TRANSPORTADOR FARMACEUTICAMENTE ACEPTABLE. (I) DONDE LOS SIMBOLOS QUE APARECEN EN LA FORMULA ANTERIOR, TIENEN LOS SIGNIFICADOS SIGUIENTES, RESPECTIVAMENTE: X: N, CH, R: UN GRUPO IMIDAZOLILO, O UN GRUPO DIALQUILAMINO INFERIOR, R{SUP,1}: (1) UN ATOMO DE HALOGENO, UN GRUPO NITRO, CARBOXILO, AMINO, MONOO DIALQUILAMINO INFERIOR, ALCANOILO INFERIOR, ALQUILSUFINILO INFERIOR, ALQUILSULFONILO INFERIOR, O CARBAMOILO, (2) UN GRUPO ALQUILO INFERIOR O ALCOXILO INFERIOR, QUE PUEDE ESTAR SUSTITUIDO CON UN ATOMO DE HALOGENO, CON UN GRUPO CARBOXILO, O CON UN GRUPO ARILO, (3) UN GRUPO FENOXILO, QUE PUEDE ESTAR SUSTITUIDO CON UN GRUPOALCOXICARBONILO INFERIOR O CON UN GRUPO CARBOXILO, R{SUP,2}: UN GRUPO HIDROXILO, ALCOXILO INFERIOR, AMINO O MONOO DIALQUILAMINO INFERIOR, A: UN GRUPO ALQUILENO INFERIOR, QUE PUEDE ESTAR SUSTITUIDO, O UN GRUPO REPRESENTADO POR LA FORMULA -O-B-, Y B: UN GRUPO ALQUILENO INFERIOR, CON LA CONDICION DE QUE, SE EXCLUYE EL CASO EN EL QUE R REPRESENTA UN GRUPO IMIDAZOLILO, R{SUP,1} REPRESENTA UN GRUPO CIANO, A REPRESENTA UN GRUPO ETILENO, Y R{SUP,2} REPRESENTA UN GRUPO HIDROXILO.
ES95932217T 1994-09-27 1995-09-25 Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor. Expired - Lifetime ES2168383T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23190894 1994-09-27
JP5948295 1995-03-17

Publications (1)

Publication Number Publication Date
ES2168383T3 true ES2168383T3 (es) 2002-06-16

Family

ID=26400527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932217T Expired - Lifetime ES2168383T3 (es) 1994-09-27 1995-09-25 Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.

Country Status (16)

Country Link
US (1) US6096743A (es)
EP (1) EP0784054B1 (es)
KR (1) KR100392151B1 (es)
CN (1) CN1067387C (es)
AT (1) ATE209644T1 (es)
CA (1) CA2199468C (es)
DE (1) DE69524246T2 (es)
DK (1) DK0784054T3 (es)
ES (1) ES2168383T3 (es)
HU (1) HU223945B1 (es)
MX (1) MX9702244A (es)
PL (1) PL181532B1 (es)
PT (1) PT784054E (es)
RU (1) RU2149873C1 (es)
UA (1) UA44283C2 (es)
WO (1) WO1996010023A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE19519979A1 (de) * 1995-05-24 1996-11-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
AU6310498A (en) 1997-03-14 1998-10-12 Meiji Seika Kaisha Ltd. Physiologically active substance pf1191 and process for producing the same
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL139783A0 (en) 1998-06-01 2002-02-10 Shionogi & Co Cyanoiminoquinoxaline derivates
WO2000047567A1 (en) 1999-02-15 2000-08-17 Eisai Co., Ltd. Heterodiazinone derivatives
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6709667B1 (en) 1999-08-23 2004-03-23 Conceptus, Inc. Deployment actuation system for intrafallopian contraception
EP1736468A3 (en) * 2000-01-24 2007-01-03 NeuroSearch A/S Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
US7029872B2 (en) * 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2003220825A1 (en) * 2002-03-29 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for glioblastoma
US20050130978A1 (en) * 2002-04-17 2005-06-16 Masamichi Yuda Novel crystal of quinoxalinedione derivative anhydride
CA2490688A1 (en) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agent for brain hemorrhage
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JP5180816B2 (ja) * 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
EP2151436B1 (en) * 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
WO2020124090A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
JPWO2023042888A1 (es) 2021-09-15 2023-03-23
JPWO2023042887A1 (es) 2021-09-15 2023-03-23

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH07165756A (ja) * 1993-12-14 1995-06-27 Yamanouchi Pharmaceut Co Ltd ヒドロキシキノキサリンジオン誘導体
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Also Published As

Publication number Publication date
WO1996010023A1 (en) 1996-04-04
KR100392151B1 (ko) 2003-11-20
EP0784054A1 (en) 1997-07-16
PL320059A1 (en) 1997-09-01
RU2149873C1 (ru) 2000-05-27
MX9702244A (es) 1997-06-28
EP0784054B1 (en) 2001-11-28
AU684392B2 (en) 1997-12-11
CA2199468C (en) 2006-06-06
AU3533795A (en) 1996-04-19
DK0784054T3 (da) 2002-03-25
PL181532B1 (pl) 2001-08-31
DE69524246T2 (de) 2002-06-27
HUT77442A (hu) 1998-04-28
CN1067387C (zh) 2001-06-20
US6096743A (en) 2000-08-01
UA44283C2 (uk) 2002-02-15
PT784054E (pt) 2002-05-31
KR970706274A (ko) 1997-11-03
ATE209644T1 (de) 2001-12-15
EP0784054A4 (en) 1998-01-07
DE69524246D1 (de) 2002-01-10
HU223945B1 (hu) 2005-03-29
CN1168670A (zh) 1997-12-24
CA2199468A1 (en) 1996-04-04

Similar Documents

Publication Publication Date Title
PT784054E (pt) Derivados de tetraidroquinoxalinadiona 1,2,3,4 e sua utilizacao como antagonistas do receptor glutamato
AU651986B2 (en) Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
DK0622361T3 (da) Heterocykliske forbindelser som bradykininantagonister
CA2311742A1 (en) 6-amino-9-benzyl-8-hydroxypurine derivatives
ATE448226T1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
IL101785A0 (en) Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0638567A4 (en) ADENOSINE INHIBITORS.
MX9306831A (es) Nuevos compuestos heterociclicos.
RU97104870A (ru) 1,2,3,4-тетрагидрохиноксалиндионовое производное
EP0976748A4 (en) PYRROLIDIN DERIVATIVES HAVING A PHOSPHOLIPASE A2 INHIBITING EFFECT
ES2091489T3 (es) Derivados de imidazol y composiciones farmaceuticas que los contienen.
DE69021855D1 (de) Quinazolinderivate und ihre Herstellung.
DK112688D0 (da) Heterocykliske forbindelser
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
DE69000224D1 (en) Thioformamidderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 784054

Country of ref document: ES